DHEA-S (Dehydroepiandrosterone Sulfate), Serum
The DHEA-S (Dehydroepiandrosterone Sulfate) Serum test measures the sulfated storage form of the primary adrenal androgen prohormone — the most analytically stable adrenal androgen marker with minimal diurnal variation, suitable for collection at any time of day.
1
Biomarkers
Blood (serum)
Sample
1–3 business days
Turnaround
No — fasting is not required for DHEA-S. Unlike unconjugated DHEA, DHEA-S has minimal diurnal variation and can be collected at any time of day without significant effect on the result. This is one of the principal analytical advantages of DHEA-S over unconjugated DHEA as the preferred adrenal androgen marker. If DHEA-S is collected alongside morning cortisol as part of an adrenal profile, morning collection (07:00–09:00) is appropriate to align with the standardised cortisol collection window — but this is for cortisol interpretability, not for DHEA-S per se.
Fasting
What is the DHEA-S test?
The DHEA-S Serum test quantifies the sulfated storage form of dehydroepiandrosterone — the most analytically stable and clinically preferred marker of adrenal androgen output. DHEA-S is ordered as the first-line adrenal androgen assessment test across a range of clinical indications because its analytical stability, absence of meaningful diurnal variation, and high serum concentration make it reliably measurable from a standard morning, afternoon, or random serum draw without the strict timing requirements of unconjugated DHEA. Unlike unconjugated DHEA — which falls 50–80% from morning to afternoon and is highly sensitive to acute stress at collection — DHEA-S provides a consistent, reproducible adrenal androgen status measurement that can be collected at any time during a clinical appointment without introducing interpretive ambiguity from collection timing variability. The primary clinical applications of DHEA-S span adrenal androgen characterisation, adrenal disease evaluation, reproductive endocrinology, biological ageing assessment, and HPA axis functional status profiling. In androgen excess workup — hirsutism, acne, alopecia, menstrual irregularity, or virilisation — DHEA-S distinguishes adrenal androgen excess (elevated DHEA-S) from purely gonadal androgen excess (elevated testosterone with normal DHEA-S), which has direct therapeutic implications. In adrenal insufficiency assessment, DHEA-S is typically reduced alongside cortisol, adding adrenal androgen reserve data to the cortisol-based adrenal function evaluation. In ageing and integrative medicine assessment, the progressive decline in DHEA-S from its third-decade peak provides an objective age-relative biomarker of adrenal androgen reserve depletion, with implications for metabolic health, immune resilience, sexual function, musculoskeletal vitality, and cognitive reserve that are increasingly supported by observational and interventional data.
What does the DHEA-S test measure?
Dehydroepiandrosterone sulfate is the sulfate ester and principal circulating form of DHEA, produced by sulfoconjugation of DHEA at the C-3 hydroxyl position primarily by the enzyme SULT2A1 in the adrenal zona reticularis (approximately 90%) with minor contributions from hepatic and intestinal sulfation. DHEA-S is the most abundant circulating steroid hormone in humans — circulating at concentrations 300–500 times higher than unconjugated DHEA — and represents the stable, long-lived storage depot form of adrenal DHEA output. Its serum half-life of approximately 7–10 hours (versus 1–3 hours for unconjugated DHEA) and minimal diurnal variation — in contrast to the pronounced morning-to-afternoon decline of unconjugated DHEA and cortisol — make it the preferred clinical marker for adrenal androgen reserve assessment, suitable for specimen collection at any time of day without strict timing requirements. DHEA-S cannot itself bind androgen or oestrogen receptors but functions as a circulating prohormone that is desulfated peripherally by steroid sulfatase (STS) to DHEA, which is then converted through intracrine and intratissue pathways to testosterone, estradiol, and dihydrotestosterone (DHT) in target tissues including adipose, liver, skin, adrenal, and gonads. DHEA-S secretion follows the trajectory of adrenarche — rising from approximately age 6–8, peaking in the mid-twenties at 300–500 µg/dL, and declining progressively thereafter at approximately 2–3% per year through ageing (adrenopause), independent of HPA axis glucocorticoid production.
DHEA-S is the primary clinical marker for adrenal androgen reserve, adrenal androgen excess, and adrenal ageing status across multiple clinical domains. As a first-line adrenal androgen assessment marker, it localises androgen excess to an adrenal source when elevated — specifically the zona reticularis — as distinct from gonadal androgen excess from ovarian theca cells (testosterone) or peripheral androgen excess from aromatase activity. In the PCOS diagnostic workup, elevated DHEA-S (typically above 300–350 µg/dL in women) indicates adrenal androgen contribution to the androgen excess phenotype, clinically significant because adrenal-predominant PCOS responds differently to treatment than purely ovarian PCOS. In aetiological investigation of adrenal androgen excess, markedly elevated DHEA-S (above 700–800 µg/dL in adults) warrants adrenal imaging to exclude adrenal androgen-secreting adenoma or carcinoma — adrenal carcinoma characteristically produces extremely elevated DHEA-S alongside other adrenal androgens. In the assessment of adrenal ageing and HPA axis functional status, DHEA-S provides an objective, analytically stable marker of adrenal androgen reserve decline — the basis for DHEA supplementation decisions in integrative medicine and anti-ageing contexts.
Why is the DHEA-S test ordered?
- Androgen excess investigation in females — elevated DHEA-S alongside testosterone localises androgen excess to an adrenal-predominant pattern; DHEA-S above 350 µg/dL specifically indicates adrenal zona reticularis hyperactivity as the primary or contributing androgen source, with important treatment implications distinguishing adrenal from ovarian androgen excess
- PCOS subtype characterisation — DHEA-S alongside testosterone, SHBG, LH, FSH, and fasting insulin to characterise the adrenal androgen contribution to the PCOS phenotype; the classic PCOS lipid pattern (elevated triglycerides, low HDL-C, elevated LDL-C) alongside elevated DHEA-S indicates the insulin-driven adrenal PCOS subtype where insulin-sensitising therapy is the primary metabolic intervention
- Congenital adrenal hyperplasia (CAH) evaluation — markedly elevated DHEA-S alongside elevated androstenedione with reduced cortisol in a patient with virilisation, early pubic hair development, or inappropriate sexual precocity supports non-classical CAH; 17-hydroxyprogesterone (17-OHP) is the primary CAH confirmation marker, with DHEA-S providing the adrenal androgen excess corroborating context
- Adrenal androgen-secreting tumour screening — DHEA-S above 700–800 µg/dL in an adult without an alternative explanation (exogenous DHEA supplementation, severe insulin resistance) warrants adrenal imaging to exclude adrenal adenoma or carcinoma; adrenal carcinoma typically produces extremely elevated DHEA-S (often >1000 µg/dL) alongside other adrenal androgens with rapid onset of virilisation
- Adrenal insufficiency comprehensive assessment — DHEA-S alongside morning cortisol and ACTH to characterise the full adrenal cortical hormone profile in patients with suspected adrenal insufficiency, characterising not only glucocorticoid but also androgen compartment loss — relevant to adrenal replacement completeness assessment
- Biological ageing, HPA axis functional status, and vitality assessment in integrative medicine — DHEA-S as an objective adrenal androgen reserve marker in the context of unexplained fatigue, reduced libido, decreased musculoskeletal vitality, immune vulnerability, mood decline, and cognitive symptoms attributed to adrenal ageing; the cortisol:DHEA-S ratio quantifies the catabolic-to-anabolic hormonal balance
- Pre- and post-DHEA supplementation monitoring — DHEA-S as the primary monitoring marker before initiating bioidentical DHEA supplementation and at 4–8 week intervals after initiation to confirm therapeutic range achievement without over-supplementation to supraphysiological levels
- Paediatric adrenarche and premature adrenarche assessment — DHEA-S as the earliest biochemical marker of adrenal androgen production onset at adrenarche; premature adrenarche (DHEA-S above age-specific reference ranges before age 8 in girls and age 9 in boys) requires evaluation to distinguish benign isolated premature adrenarche from pathological causes including non-classical CAH and adrenal tumour
Sample collection and turnaround
Sample type
Blood (serum)
Fasting required
No — fasting is not required for DHEA-S. Unlike unconjugated DHEA, DHEA-S has minimal diurnal variation and can be collected at any time of day without significant effect on the result. This is one of the principal analytical advantages of DHEA-S over unconjugated DHEA as the preferred adrenal androgen marker. If DHEA-S is collected alongside morning cortisol as part of an adrenal profile, morning collection (07:00–09:00) is appropriate to align with the standardised cortisol collection window — but this is for cortisol interpretability, not for DHEA-S per se.
Collection method
Venipuncture at patient service centre
Turnaround
1–3 business days
Collection notes
Standard venipuncture into a serum separator tube (SST / gold top). No special preparation or timing requirements apply. Document on the requisition form: (1) current DHEA supplementation — bioidentical DHEA dose, formulation, and most recent dose timing; this is the most critical confounding variable to document; (2) oral contraceptive or exogenous oestrogen use — type, dose, and duration; (3) exogenous corticosteroid use — all routes (systemic, inhaled, topical, injected), dose, duration, and timing of most recent dose; (4) known insulin resistance, PCOS, or metabolic syndrome; (5) acute illness or hospitalisation within 4 weeks; (6) paediatric patients — document exact age and whether premature adrenarche or late puberty is the clinical question; (7) whether concurrent cortisol measurement is being performed for cortisol:DHEA-S ratio calculation. # REVIEWER FLAG: Confirm LabCorp SST tube type, minimum serum volume, centrifugation and separation requirements, and stability data for DHEA-S before publication.
Specimen requirements
Minimum 0.5 mL serum. Centrifuge and separate serum from cells within 2 hours of collection. Stable at 2–8°C for up to 7 days; stable frozen at −20°C for extended storage. # REVIEWER FLAG: Confirm minimum volume and stability data with LabCorp assay documentation.
What can affect DHEA-S results?
Oral DHEA supplementation — bioidentical DHEA capsules or tablets — is hepatically sulfated to DHEA-S by SULT2A1, substantially elevating serum DHEA-S within days of initiation. Unlike unconjugated DHEA (which produces a rapid peak and fast decline), supplemental DHEA produces a more prolonged DHEA-S elevation reflecting the sulfated storage form accumulation. Pre-supplementation baseline DHEA-S must be established before initiating DHEA therapy. Monitoring specimens must document the dose, formulation, and timing of most recent dose relative to collection for interpretable serial comparison. A DHEA-S above the age-appropriate upper reference limit in an otherwise asymptomatic patient should always prompt enquiry about DHEA supplementation before adrenal pathology is investigated.
Insulin stimulates adrenal zona reticularis DHEA production through upregulation of adrenal steroidogenic enzymes, particularly CYP17A1 17,20-lyase activity — the key step for adrenal androgen synthesis. In patients with significant insulin resistance — PCOS, metabolic syndrome, type 2 diabetes — elevated insulin drives adrenal DHEA-S production above the age-expected level independently of primary adrenal pathology. DHEA-S elevation in the context of insulin resistance should prompt assessment of fasting insulin and HOMA-IR before attributing DHEA-S excess to a primary adrenal androgen disorder.
Systemic glucocorticoids suppress ACTH secretion through negative feedback at the hypothalamus and pituitary, reducing adrenocortical stimulation across all three adrenal cortical zones — including the zona reticularis that produces DHEA-S. Patients on long-term systemic corticosteroids or high-dose inhaled corticosteroids have predictably suppressed DHEA-S that reflects pharmacological HPA axis suppression rather than intrinsic adrenal reserve depletion. All exogenous corticosteroid use — type, dose, route, duration — must be documented on the requisition form for accurate DHEA-S interpretation.
Combined oral contraceptives suppress the hypothalamic-pituitary-adrenal axis through oestrogen-driven suppression of ACTH pulse amplitude and through direct hepatic upregulation of DHEA-S clearance enzymes. OCP use consistently reduces serum DHEA-S by 20–40% — a patient on OCP will have systematically lower DHEA-S than her intrinsic adrenal androgen production would generate, and her true adrenal reserve cannot be assessed from a DHEA-S specimen collected during OCP use. Menopausal HRT with oral oestrogen produces a smaller but similar suppressive effect. All oestrogen-containing medications must be documented on the requisition form.
DHEA-S follows a predictable age-dependent trajectory that is the dominant biological determinant of the absolute DHEA-S value in healthy adults — far more influential than acute physiological variables. DHEA-S peaks at 200–500 µg/dL in the mid-twenties and declines at approximately 2–3% per year, falling to 10–50% of peak values by the seventh decade. This age-related decline (adrenopause) is independent of the cortisol diurnal rhythm and progresses regardless of health status. Without age-stratified reference ranges — which LabCorp provides — DHEA-S values in older adults would systematically appear abnormally low if compared against young adult reference ranges. Age-stratified interpretation is mandatory for DHEA-S.
Acute severe illness, major surgery, trauma, and chronic inflammatory disease reduce DHEA-S through multiple mechanisms: cytokine-mediated suppression of zona reticularis activity (IL-1, IL-6, and TNF-α inhibit adrenal DHEA synthesis); HPA axis glucocorticoid priority diverting pregnenolone toward cortisol at the expense of DHEA synthesis under sustained ACTH stimulation; and nutritional depletion impairing steroidogenic substrate availability. DHEA-S measured during acute illness or in the context of chronic inflammatory disease reflects illness-induced suppression rather than intrinsic adrenal reserve and should be repeated following clinical recovery before therapeutic conclusions are drawn.
What do DHEA-S results mean?
Elevated
Elevated DHEA-S above the age-stratified upper reference limit requires investigation proportional to the degree of elevation. Mildly to moderately elevated DHEA-S (up to approximately 1.5× the upper reference limit) in a premenopausal woman with features of PCOS most likely reflects insulin-driven adrenal androgen excess — assess fasting insulin, testosterone, SHBG, LH:FSH ratio, and exclude exogenous DHEA supplementation. Moderately elevated DHEA-S (350–700 µg/dL in adult women) in a patient with progressive virilisation, acne, or hirsutism without PCOS features warrants 17-hydroxyprogesterone measurement to exclude non-classical CAH (early morning follicular phase 17-OHP above 2 ng/mL warrants ACTH stimulation testing). Markedly elevated DHEA-S (above 700–800 µg/dL in adult women or proportionally elevated in men) without exogenous DHEA supplementation or severe insulin resistance warrants adrenal imaging (CT adrenals) to exclude adrenal adenoma or carcinoma — adrenal carcinoma typically produces extreme elevations above 1000 µg/dL with rapid onset of symptoms.
Normal
DHEA-S within the age-stratified reference range confirms adequate adrenal androgen reserve for the patient's decade of life. In a symptomatic patient with fatigue, reduced vitality, or diminished libido but a DHEA-S within the reference range, the functional medicine approach considers the relative position within the reference interval — a DHEA-S in the lower tertile of the age-appropriate range may guide supplementation in the context of clinical symptoms and the cortisol:DHEA-S ratio, even though the result does not meet the diagnostic threshold for deficiency. A normal DHEA-S effectively excludes major adrenal androgen excess disorders and markedly elevated adrenal androgen-secreting tumours from the differential.
Reduced
Low DHEA-S below the age-stratified lower reference limit in a patient not on corticosteroids or OCP indicates reduced adrenal zona reticularis secretory output. In younger patients, concurrent low morning cortisol and elevated ACTH suggests primary adrenal insufficiency (Addison's disease) — DHEA-S is reduced alongside cortisol in primary adrenal insufficiency because the entire adrenal cortex is failing. In secondary adrenal insufficiency from pituitary pathology, DHEA-S is similarly reduced due to absent ACTH drive. In the functional medicine context, low DHEA-S in the context of clinical fatigue, reduced libido, decreased musculoskeletal vitality, and immune vulnerability — particularly alongside normal or elevated cortisol (elevated cortisol:DHEA-S ratio) — is interpreted as adrenal androgen reserve depletion driving the catabolic-predominant HPA state associated with chronic stress and adrenal ageing. The cortisol:DHEA-S ratio — often simplified as morning serum cortisol (µg/dL) divided by DHEA-S (µg/dL) — is the key HPA balance index in functional medicine, with an elevated ratio indicating catabolic stress dominance.
Note: Age-stratified reference range application is mandatory — DHEA-S must always be compared against the patient's age- and sex-specific reference interval rather than a single adult reference range. The most common interpretive error is comparing a 60-year-old patient's DHEA-S against a young adult reference range and generating a misleading 'low' result that overstates clinical significance. The second important caveat is that exogenous DHEA supplementation must always be excluded before attributing elevated DHEA-S to adrenal pathology — it is the most common non-pathological cause of elevated DHEA-S results in integrative medicine patients. The third caveat is the OCP and exogenous oestrogen suppression effect — DHEA-S in women on OCP systematically underestimates intrinsic adrenal reserve and should not be used to assess adrenal DHEA-S output unless OCP has been discontinued and an adequate washout period has elapsed.
Frequently asked questions
DHEA-S measures dehydroepiandrosterone sulfate — the sulfated, long-lived storage form of DHEA produced almost exclusively by the adrenal zona reticularis. It is preferred over unconjugated DHEA for routine adrenal androgen assessment because of its analytical stability: DHEA-S has minimal diurnal variation (unlike unconjugated DHEA, which falls 50–80% from morning to afternoon), a longer half-life of 7–10 hours, and can be collected at any time of day without strict timing requirements. These properties make DHEA-S the most practically reliable single-draw adrenal androgen marker in clinical practice.
How to access the DHEA-S test
The DHEA-S reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: May 24, 2026
Last reviewed: May 24, 2026
- Orentreich N, et al. Age changes and sex differences in serum dehydroepiandrosterone sulfate concentrations throughout adulthood. J Clin Endocrinol Metab. (1984)
- Labrie F, et al. DHEA and its transformation into androgens and estrogens in peripheral target tissues: intracrinology. Front Neuroendocrinol. (2001)
- Bornstein SR, et al. Diagnosis and Treatment of Primary Adrenal Insufficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. (2016)
- Traish AM, et al. DHEA — a precursor of androgen and estrogen in humans. J Sex Med. (2011)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
adrenal stress
DHEA Unconjugated
The DHEA Unconjugated test measures the biologically active, unsulfated form of dehydroepiandrosterone in serum — the rapidly fluctuating adrenal androgen precursor fraction distinct from the sulfated storage form DHEA-S. It requires standardised morning collection between 08:00 and 09:00 hours due to its pronounced diurnal variation and is specifically indicated for real-time adrenal secretory…
adrenal stress
Serum Cortisol
The Cortisol Serum test quantifies total circulating cortisol — bound and free fractions combined — providing the primary biochemical assessment of HPA axis function and adrenocortical output. Morning collection (07:00–09:00) is the standard for adrenal insufficiency screening — a value above 18–20 µg/dL effectively excludes adrenal insufficiency; below 3 µg/dL strongly confirms it;
female hormones
17-OHP
The 17-hydroxyprogesterone test measures serum 17-OHP, a steroid intermediate that accumulates in 21-hydroxylase deficiency, the most common form of congenital adrenal hyperplasia. It is the first-line biochemical test for diagnosing classic and non-classic CAH, distinguishing it from other causes of virilisation and hyperandrogenism, with borderline values prompting cosyntropin stimulation for…